课题基金 / 基金详情

项目摘要

项目成果

John F. Dipersio的其他基金

相似基金

相关文献

中文摘要
翻译
该项目的长期目标是确定与AML复发/耐药相关的遗传变化
英文摘要
The long term goal of this project is to define the genetic changes associated with AML relapse/resistance to chemotherapy. This work requires paired samples of de novo and relapsed AML cells that are nearly homogeneous in composition, and tissue culture and mouse models to validate the functional consequences of these genetic changes. The Genomics of AML PPG provides the appropriate infrastructure for this project. We will investigate AML relapse/resistance via the following Specific Aims: Specific Aim 1: We will define the genetic changes that occur in murine APL cell lines selected for chemotherapeutic resistance in vitro. We have generated 10 "parental" murine APL tumor cell lines. We will generate a total of 10 murine APL tumor cell lines and paired subclones that are resistant to daunorubicin (DNR), and/or Ara-C both in vitro and in vivo. Using these well-defined clonal populations of cells, we will perform gene expression profiling and we will define acquired microdeletions and amplifications using array-based comparative genomic hybridization (CGH) with the NimbleGen 2.1M murine oligomer array. Genes that are consistently dysregulated, deleted, or amplified in DNR or Ara-C resistant subclones will be validated with qPCR approaches. Selected genes identified with these array-based genomic screens will be resequenced to define more subtle genetic changes. Functional validation will be performed using forced overexpression and shRNAi knock-down approaches. Specific Aim 2: We will define the genetic changes that contribute to AML relapse by comparing the genomes of AML cells obtained at initial presentation vs. first relapse. Because most relapsed samples are not well matched to the paired de novo samples in terms of cellular composition, we will purify AML blasts by sorting "blast gate" AML cells from the cte novo and relapsed sample pairs for at least 20 AML patients. Using RNA and DMA from these paired, enriched samples, we will perform array based expression profiling and high resolution array based CGH using the 2.1M human oligomer arrays from NimbleGen. The altered genes identified in Aims 1 and 2 will be used to select a subset of target genes for resequencing and biologic validation in the mouse APL model described in Aim 1. Specific Aim 3: We will assess the role of the bone marrow microenvironment on AML resistance and relapse. We will use a unique mouse model in which genetically-marked murine APL cells home to and expand in the mouse bone marrow (BM). We will determine whether interruption of the protective AML cell-stromal interaction (using inhibitors of the SDF-1-CXCR4 and the VCAM-1-VLA-4 axes) can sensitize APL cells to chemotherapy in vivo. Finally, we have devised a clinical trial in which we will test the role of a small molecule inhibitor of the CXCR4-SDF-1 axis given immediately prior to salvage chemotherapy in patients with relapsed AML to enhance remission rates and overall survival.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 6- Targeting AML using bispecific and antibody drug conjugates
  • 批准号:
    10615336
  • 项目类别:
  • 资助金额:
    $27.03万
  • 财政年份:
    2021
  • 负责人:
    John F. Dipersio
  • 依托单位:
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
  • 批准号:
    10469493
  • 项目类别:
  • 资助金额:
    $89.67万
  • 财政年份:
    2017
  • 负责人:
    John F. Dipersio
  • 依托单位:
Pilot Projects and Trans-Network Activities Core
  • 批准号:
    9446709
  • 项目类别:
  • 资助金额:
    $25.44万
  • 财政年份:
    2017
  • 负责人:
    John F. Dipersio
  • 依托单位:
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies
  • 批准号:
    10001462
  • 项目类别:
  • 资助金额:
    $91.49万
  • 财政年份:
    2017
  • 负责人:
    John F. Dipersio
  • 依托单位:
国内基金
海外基金
E2F1 基因多态性与急性髓系白血病Ara-C 化疗敏感性及预后的关联性研究
  • 批准号:
    2021JJ41011
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    刘雁峰
  • 依托单位:
RAS基因突变对脱氧胞苷激酶介导的ARA-C的敏感性影响及其分子机制研究
  • 批准号:
    81270621
  • 项目类别:
    面上项目
  • 资助金额:
    60.0万元
  • 批准年份:
    2012
  • 负责人:
    李军民
  • 依托单位: